Morgan Stanley Boosts Haemonetics Corporation (HAE) Price Target to $51.00
Haemonetics Corporation (NYSE:HAE) had its price objective boosted by Morgan Stanley from $43.00 to $51.00 in a research note issued to investors on Thursday morning. They currently have an equal weight rating on the medical instruments supplier’s stock.
A number of other research firms have also recently commented on HAE. Craig Hallum reiterated a hold rating and set a $50.00 target price (up previously from $40.00) on shares of Haemonetics Corporation in a research report on Wednesday. Barrington Research lifted their target price on Haemonetics Corporation from $48.00 to $57.00 and gave the stock an outperform rating in a research report on Wednesday. Zacks Investment Research upgraded Haemonetics Corporation from a hold rating to a buy rating and set a $52.00 target price on the stock in a research report on Wednesday, October 25th. TheStreet upgraded Haemonetics Corporation from a c rating to a b- rating in a research report on Monday, August 7th. Finally, BidaskClub raised Haemonetics Corporation from a strong sell rating to a sell rating in a report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Haemonetics Corporation has a consensus rating of Hold and an average target price of $51.33.
Haemonetics Corporation (NYSE HAE) traded down $0.40 on Thursday, hitting $54.52. The stock had a trading volume of 695,600 shares, compared to its average volume of 452,245. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.72. Haemonetics Corporation has a twelve month low of $36.44 and a twelve month high of $55.10. The firm has a market capitalization of $2,879.64, a PE ratio of 33.45, a P/E/G ratio of 4.08 and a beta of 0.91.
Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.07. Haemonetics Corporation had a return on equity of 11.16% and a net margin of 0.50%. The business had revenue of $225.40 million for the quarter, compared to analysts’ expectations of $219.12 million. During the same quarter in the previous year, the firm earned $0.38 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. equities research analysts forecast that Haemonetics Corporation will post 1.7 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/12/morgan-stanley-boosts-haemonetics-corporation-hae-price-target-to-51-00.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its holdings in shares of Haemonetics Corporation by 1.1% during the second quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 300 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Haemonetics Corporation by 48,854.9% during the first quarter. BlackRock Inc. now owns 6,289,728 shares of the medical instruments supplier’s stock worth $255,175,000 after buying an additional 6,276,880 shares during the last quarter. Aperio Group LLC grew its holdings in shares of Haemonetics Corporation by 15.0% during the second quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock worth $422,000 after buying an additional 1,393 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Haemonetics Corporation by 12.2% during the second quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock worth $928,000 after buying an additional 2,553 shares during the last quarter. Finally, Kirr Marbach & Co. LLC IN grew its holdings in shares of Haemonetics Corporation by 56.3% during the second quarter. Kirr Marbach & Co. LLC IN now owns 11,300 shares of the medical instruments supplier’s stock worth $446,000 after buying an additional 4,070 shares during the last quarter.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Stock Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related stocks with our FREE daily email newsletter.